<DOC>
	<DOCNO>NCT01535391</DOCNO>
	<brief_summary>This study open-label , multicentric , phase IIIb study NILOTINIB administer orally twice daily 24 month indefinitely interest patient . The primary objective trial evaluate efficacy nilotinib , 300 mg twice daily dose increase 400 mg twice daily case suboptimal response failure ( exclude patient fail progression ABP ) , population patient Ph-positive , BCR-ABL positive CML early CP .</brief_summary>
	<brief_title>Nilotinib PH+ , BCR- , ABL+ CML Patients</brief_title>
	<detailed_description>This study open-label , multicentric , phase IIIb study NILOTINIB administer orally dose 300 mg twice daily ( total daily dose 600 mg daily ) 24 month ( study core ) , indefinitely interest patient ( drug give free-of-charge 24 month patient achieve CMR4 24 month absence safety concern ) . Nilotinib dose increase 400 mg BID case suboptimal response failure ( exception patient fail progression ABP : case progression ABP , patient treat study drug choice treatment physician ) . Study duration estimate 6 year , 1 year estimate enrollment , 2 year therapy duration . Thereafter , information course survival due 3 year . The main data analysis perform patient complete 24 month treatment ( discontinue earlier ) . Safety tolerability profile assess collect hematologic non-hematologic adverse event , laboratory examination ECG data . The molecular response assess use GIMEMA standardize molecular laboratory ( Labnet network ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Age ≥ 18 Male female patient diagnosis Ph+ and/or BCRABL+ CML Early chronic phase ( within 6 month diagnosis ) Pretreatment Hydroxyurea Anagrelide duration 3 month and/or pretreatment Imatinib 30 day permit Normal serum level potassium , magnesium , phosphorus , total calcium correct serum albumin phosphorus , correctable within normal limit supplement prior first dose study medication Written inform consent prior study procedure perform AST ALT ≤ 2.5 x ULN ≤ 5.0 x ULN consider due leukaemia Alkaline phosphatase ≤ 2.5 x ULN unless consider due leukaemia Total direct bilirubin ≤ 1.5 x ULN , except know Mb . Gilbert Serum creatinine ≤ 1.5 x ULN Known impair cardiac function , include follow : LVEF &lt; 45 % Complete leave bundle branch block Right bundle branch block plus leave anterior hemiblock , bifascicular block Use ventricularpaced pacemaker Congenital long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec screen ECG . If QTc &gt; 450 msec electrolyte within normal range Nilotinib dosing , electrolytes correct patient rescreened QTc criterion . Myocardial infarction within 12 month prior start study drug Other clinical significant heart disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ) Serum lipase amylase &gt; 1.5 x ULN ( upper limit normal ) history acute ( i.e. , within 1 year start study medication ) chronic pancreatitis Other concurrent uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection , acute chronic liver renal disease ) could cause unacceptable safety risk compromise compliance protocol Impaired gastrointestinal function disease may alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Concomitant medication potential QT prolongation ( see link complete list : http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm ) Concomitant medication know interact CYP450 isoenzymes ( CYP3A4 , CYP2C9 , andCYP2C8 : link complete list : http : //medicine.iupui.edu/flockhart/table.html.. Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy Patients pregnant breast feeding , woman reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 48 hour prior administration nilotinib ) . Patients history another primary malignancy currently clinically significant currently require active intervention . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Myeloid Leukemia ,</keyword>
	<keyword>Nilotinib ,</keyword>
	<keyword>Philadelphia positive ,</keyword>
	<keyword>BCR-ABL+</keyword>
	<keyword>Early chronic phase</keyword>
</DOC>